|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: BAG4 |
Gene summary for BAG4 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | BAG4 | Gene ID | 9530 |
| Gene name | BAG cochaperone 4 | |
| Gene Alias | BAG-4 | |
| Cytomap | 8p11.23 | |
| Gene Type | protein-coding | GO ID | GO:0001667 | UniProtAcc | O95429 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 9530 | BAG4 | LZE2T | Human | Esophagus | ESCC | 1.21e-04 | 6.85e-01 | 0.082 |
| 9530 | BAG4 | LZE4T | Human | Esophagus | ESCC | 1.48e-15 | 6.08e-01 | 0.0811 |
| 9530 | BAG4 | LZE7T | Human | Esophagus | ESCC | 1.09e-02 | 1.97e-01 | 0.0667 |
| 9530 | BAG4 | LZE8T | Human | Esophagus | ESCC | 3.95e-03 | 9.27e-02 | 0.067 |
| 9530 | BAG4 | LZE20T | Human | Esophagus | ESCC | 1.51e-03 | 1.24e-01 | 0.0662 |
| 9530 | BAG4 | LZE24T | Human | Esophagus | ESCC | 2.77e-21 | 5.15e-01 | 0.0596 |
| 9530 | BAG4 | P2T-E | Human | Esophagus | ESCC | 1.69e-34 | 6.26e-01 | 0.1177 |
| 9530 | BAG4 | P4T-E | Human | Esophagus | ESCC | 3.97e-35 | 7.90e-01 | 0.1323 |
| 9530 | BAG4 | P5T-E | Human | Esophagus | ESCC | 1.75e-08 | 1.55e-01 | 0.1327 |
| 9530 | BAG4 | P8T-E | Human | Esophagus | ESCC | 5.86e-18 | 3.44e-01 | 0.0889 |
| 9530 | BAG4 | P9T-E | Human | Esophagus | ESCC | 2.99e-08 | 2.57e-01 | 0.1131 |
| 9530 | BAG4 | P10T-E | Human | Esophagus | ESCC | 1.09e-29 | 5.75e-01 | 0.116 |
| 9530 | BAG4 | P11T-E | Human | Esophagus | ESCC | 4.46e-15 | 5.45e-01 | 0.1426 |
| 9530 | BAG4 | P12T-E | Human | Esophagus | ESCC | 4.04e-32 | 5.77e-01 | 0.1122 |
| 9530 | BAG4 | P15T-E | Human | Esophagus | ESCC | 5.27e-97 | 2.22e+00 | 0.1149 |
| 9530 | BAG4 | P16T-E | Human | Esophagus | ESCC | 1.06e-27 | 3.51e-01 | 0.1153 |
| 9530 | BAG4 | P17T-E | Human | Esophagus | ESCC | 4.73e-03 | 3.35e-01 | 0.1278 |
| 9530 | BAG4 | P20T-E | Human | Esophagus | ESCC | 6.77e-24 | 5.52e-01 | 0.1124 |
| 9530 | BAG4 | P21T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.04e-01 | 0.1617 |
| 9530 | BAG4 | P22T-E | Human | Esophagus | ESCC | 7.30e-15 | 2.51e-01 | 0.1236 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0031032110 | Thyroid | PTC | actomyosin structure organization | 91/5968 | 196/18723 | 1.35e-05 | 1.45e-04 | 91 |
| GO:009717815 | Thyroid | PTC | ruffle assembly | 28/5968 | 44/18723 | 1.46e-05 | 1.56e-04 | 28 |
| GO:003223323 | Thyroid | PTC | positive regulation of actin filament bundle assembly | 36/5968 | 63/18723 | 2.98e-05 | 2.86e-04 | 36 |
| GO:003083823 | Thyroid | PTC | positive regulation of actin filament polymerization | 51/5968 | 99/18723 | 3.77e-05 | 3.48e-04 | 51 |
| GO:00903176 | Thyroid | PTC | negative regulation of intracellular protein transport | 26/5968 | 42/18723 | 5.91e-05 | 5.21e-04 | 26 |
| GO:00323877 | Thyroid | PTC | negative regulation of intracellular transport | 33/5968 | 58/18723 | 7.13e-05 | 6.19e-04 | 33 |
| GO:001092116 | Thyroid | PTC | regulation of phosphatase activity | 44/5968 | 84/18723 | 7.53e-05 | 6.48e-04 | 44 |
| GO:001076115 | Thyroid | PTC | fibroblast migration | 28/5968 | 47/18723 | 8.25e-05 | 7.00e-04 | 28 |
| GO:005149615 | Thyroid | PTC | positive regulation of stress fiber assembly | 30/5968 | 52/18723 | 1.06e-04 | 8.56e-04 | 30 |
| GO:0034612111 | Thyroid | PTC | response to tumor necrosis factor | 109/5968 | 253/18723 | 1.08e-04 | 8.69e-04 | 109 |
| GO:0045785112 | Thyroid | PTC | positive regulation of cell adhesion | 176/5968 | 437/18723 | 1.10e-04 | 8.83e-04 | 176 |
| GO:19049507 | Thyroid | PTC | negative regulation of establishment of protein localization | 61/5968 | 131/18723 | 3.01e-04 | 2.12e-03 | 61 |
| GO:00512246 | Thyroid | PTC | negative regulation of protein transport | 59/5968 | 127/18723 | 4.04e-04 | 2.71e-03 | 59 |
| GO:0071356111 | Thyroid | PTC | cellular response to tumor necrosis factor | 96/5968 | 229/18723 | 8.24e-04 | 5.10e-03 | 96 |
| GO:00434918 | Thyroid | PTC | protein kinase B signaling | 88/5968 | 211/18723 | 1.59e-03 | 8.81e-03 | 88 |
| GO:00353058 | Thyroid | PTC | negative regulation of dephosphorylation | 24/5968 | 45/18723 | 2.28e-03 | 1.20e-02 | 24 |
| GO:00331356 | Thyroid | PTC | regulation of peptidyl-serine phosphorylation | 62/5968 | 144/18723 | 3.05e-03 | 1.50e-02 | 62 |
| GO:0051346112 | Thyroid | PTC | negative regulation of hydrolase activity | 146/5968 | 379/18723 | 3.33e-03 | 1.62e-02 | 146 |
| GO:00510518 | Thyroid | PTC | negative regulation of transport | 176/5968 | 470/18723 | 5.44e-03 | 2.49e-02 | 176 |
| GO:00107624 | Thyroid | PTC | regulation of fibroblast migration | 19/5968 | 36/18723 | 7.38e-03 | 3.16e-02 | 19 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0466810 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa0466817 | Esophagus | ESCC | TNF signaling pathway | 89/4205 | 114/8465 | 3.36e-10 | 4.01e-09 | 2.06e-09 | 89 |
| hsa046689 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
| hsa0466816 | Oral cavity | OSCC | TNF signaling pathway | 82/3704 | 114/8465 | 8.30e-10 | 9.59e-09 | 4.88e-09 | 82 |
| hsa0466822 | Oral cavity | LP | TNF signaling pathway | 49/2418 | 114/8465 | 6.51e-04 | 3.29e-03 | 2.12e-03 | 49 |
| hsa0466832 | Oral cavity | LP | TNF signaling pathway | 49/2418 | 114/8465 | 6.51e-04 | 3.29e-03 | 2.12e-03 | 49 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| BAG4 | SNV | Missense_Mutation | novel | c.602G>A | p.Arg201Lys | p.R201K | O95429 | protein_coding | deleterious(0.01) | benign(0.055) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| BAG4 | SNV | Missense_Mutation | c.190G>A | p.Gly64Arg | p.G64R | O95429 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.752) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BAG4 | SNV | Missense_Mutation | c.1115N>T | p.Ser372Leu | p.S372L | O95429 | protein_coding | deleterious(0.02) | benign(0.261) | TCGA-D8-A27G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| BAG4 | SNV | Missense_Mutation | novel | c.158N>C | p.Arg53Pro | p.R53P | O95429 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.992) | TCGA-LL-A7SZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| BAG4 | SNV | Missense_Mutation | novel | c.1164N>C | p.Glu388Asp | p.E388D | O95429 | protein_coding | tolerated(0.05) | probably_damaging(0.925) | TCGA-S3-AA12-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| BAG4 | insertion | Frame_Shift_Ins | novel | c.1139_1140insGGGGTTTCACCTTGTTAGCCAGGATGGTC | p.Ile380MetfsTer28 | p.I380Mfs*28 | O95429 | protein_coding | TCGA-A2-A0EO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| BAG4 | SNV | Missense_Mutation | c.551N>T | p.Ser184Phe | p.S184F | O95429 | protein_coding | deleterious(0) | benign(0.003) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
| BAG4 | SNV | Missense_Mutation | c.5N>T | p.Ser2Leu | p.S2L | O95429 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.988) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| BAG4 | insertion | Frame_Shift_Ins | novel | c.1052_1053insAT | p.Thr352SerfsTer47 | p.T352Sfs*47 | O95429 | protein_coding | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | ||
| BAG4 | SNV | Missense_Mutation | c.1000N>A | p.Leu334Ile | p.L334I | O95429 | protein_coding | tolerated(0.19) | benign(0.146) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |